Manns, MP; Bourliere, M; Benhamou, Y et al.
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infectionJOURNAL OF HEPATOLOGY. Bd. 54. H. 6. 2011 S. 1114-1122
Mauss, S; Schober, A; Lutz, T et al.
Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and RibavirinGASTROENTEROLOGY. Bd. 140. H. 5. 2011 S. S948-S948
Mauss, S; Schober, A; Lutz, T et al.
PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRINJOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S185-S185
Mayet, WJ
Preface to AGG-publications in the Journal of GastroenterologyZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 49. H. 4. 2011 S. 429-429
Wellge, BE; Sterneck, M; Teufel, A et al.
Pregnancy in primary sclerosing cholangitisGUT. Bd. 60. H. 8. 2011 S. 1117-1121
Hohler, T; Klein, M; Dellas, K et al.
Preoperative chemoradiation (CRT) with concurrent capecitabine (Cap), oxaliplatin (Ox) and bevacizumab (Bev) in patients with locally advanced rectal cancer (RC): effects on pathological complete response (pCR) and surgical complicationsONKOLOGIE. Bd. 34. 2011 S. 220-220
Marquardt, JU; Fischer, K; Teufel, A et al.
PROGNOSTIC IMPLICATIONS OF SIRT6 IN HEPATOCELLULAR CARCINOMASHEPATOLOGY. Bd. 54. 2011 S. 1285A-1285A
Neumann, H; Vieth, M; Atreya, R et al.
Prospective evaluation of the learning curve of confocal laser endomicroscopy in patients with IBDHISTOLOGY AND HISTOPATHOLOGY. Bd. 26. H. 7. 2011 S. 867-872
Eichhorn, W; Baque, P-E; Pitton, MB et al.
Prospektive, randomisierte Untersuchung der klinisch-onkologischen Effektivität der SIRT (selective transarterial Radionuklidtherapie) und der TACE (sequenzielle transarterielle Chemoembolisation) zur Behandlung des intrahepatischen cholangiozellulären Karzinoms (CCC)Der Onkologe. Bd. 17. 2011 S. 972
Gonschior, A; Gilet, H; Heisss, MM et al.
Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis AloneEUROPEAN JOURNAL OF CANCER. Bd. 47. 2011 S. S223-S223